Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Apollomics (NASDAQ:APLM) to a sell rating in a research note published on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apollomics in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Apollomics Stock Performance

Shares of Apollomics stock opened at $16.99 on Friday. Apollomics has a 1 year low of $3.66 and a 1 year high of $42.12. The business has a 50-day moving average of $19.08 and a two-hundred day moving average of $10.62.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.